Skip to content
CancerIndex

Publication

Tumour p53 mutations exhibit promoter selective dominance over wild type p53.

Authors not recorded

Oncogene2002PMID 11896595stubpubmedProvenance
Source
PubMed
Retrieved
Sep 8, 2026
Layer
normalized (units and labels harmonized; values unchanged)
Run
ING-CIVIC-20260908-000001
Published

Abstract

Abstract (excerpt)

Only the opening of the abstract is shown; abstract text may carry publisher copyright.

Data not yet available

No abstract stored. Read on PubMed

Linked entities

Linked entities (57)

How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.

Validated 57

Curated evidence

Evidence citing this paper (57)

50 items per page.

civicProvenance
Source
CIViC — Clinical Interpretation of Variants in Cancer
Dataset
CIViC evidence items
Version
civic-2026-09-08
Retrieved
Sep 8, 2026
Layer
normalized (units and labels harmonized; values unchanged)
Evidence
expert curation
License
CC0 1.0
PMID
11896595
Run
ING-CIVIC-20260908-000001
Open at source
CuratedShowing 51–57 of 57 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.
TherapyCancerTypeLevelDirection · significanceRating (1–5)StatusEvidenceSource
TP53 Y126D1
(functional)—UNRESOLVEDFunctionalDDoes Not Support Dominant Negative3accepted
EID10217

A set of previously characterized p53 mutants was tested in the yeast assay to understand their transdominant potential (dominant negative). Each mutant was expressed equally with the wild-type p53. T… (full text at CIViC)

PMID 11896595 · Monti et al., 2002 · Open in CIViC

civic
TP53 Y126S1
(functional)—UNRESOLVEDFunctionalDDoes Not Support Dominant Negative3accepted
EID10218

A set of previously characterized p53 mutants was tested in the yeast assay to understand their transdominant potential (dominant negative). Each mutant was expressed equally with the wild-type p53. T… (full text at CIViC)

PMID 11896595 · Monti et al., 2002 · Open in CIViC

civic
TP53 Y163H1
(functional)—UNRESOLVEDFunctionalDDoes Not Support Dominant Negative3accepted
EID10225

A set of previously characterized p53 mutants was tested in the yeast assay to understand their transdominant potential (dominant negative). Each mutant was expressed equally with the wild-type p53. T… (full text at CIViC)

PMID 11896595 · Monti et al., 2002 · Open in CIViC

civic
TP53 Y163N1
(functional)—UNRESOLVEDFunctionalDSupports Dominant Negative2accepted
EID10272

A set of previously characterized p53 mutants was tested in the yeast assay to understand their transdominant potential (dominant negative). Each mutant was expressed equally with the wild-type p53. T… (full text at CIViC)

PMID 11896595 · Monti et al., 2002 · Open in CIViC

civic
TP53 Y220H1
(functional)—UNRESOLVEDFunctionalDDoes Not Support Dominant Negative3accepted
EID10239

A set of previously characterized p53 mutants was tested in the yeast assay to understand their transdominant potential (dominant negative). Each mutant was expressed equally with the wild-type p53. T… (full text at CIViC)

PMID 11896595 · Monti et al., 2002 · Open in CIViC

civic
TP53 Y234H1
(functional)—UNRESOLVEDFunctionalDDoes Not Support Dominant Negative3accepted
EID10241

A set of previously characterized p53 mutants was tested in the yeast assay to understand their transdominant potential (dominant negative). Each mutant was expressed equally with the wild-type p53. T… (full text at CIViC)

PMID 11896595 · Monti et al., 2002 · Open in CIViC

civic
TP53 Y236S1
(functional)—UNRESOLVEDFunctionalDDoes Not Support Dominant Negative3accepted
EID10226

A set of previously characterized p53 mutants was tested in the yeast assay to understand their transdominant potential (dominant negative). Each mutant was expressed equally with the wild-type p53. T… (full text at CIViC)

PMID 11896595 · Monti et al., 2002 · Open in CIViC

civic